Bausch Health Companies Inc. BHC.TO
As ofNov 19, 2026, 1:37 PM EST
- YTD
- +31.37%
- 1 year
- +47.29%
- Market cap
- 4.69B
- Revenue (ttm)
- 11.11B
- Profit margin
- -7.57%
- EPS (ttm)
- -3.14
- Shares out
- 374.27M
- Forward P/E
- 2.05
- YTD return
- +31.37%
- 1-year return
- +47.29%
- Volume
- 228.82K
- Avg volume
- 656.49K
- Open
- 12.42
- Previous close
- 12.52
- Day's range
- 12.32 – 12.65
- 52-week range
- 6.10 – 12.66
- Beta
- 0.28
- 50-day average
- 9.39
Key statistics
- 200-day average
- 8.09
- Enterprise value
- 23.75B
- PEG ratio
- 0.02
- Price / sales
- 0.42
- Revenue growth
- 9.70%
- Free cash flow
- 1.64B
- Total cash
- 2.48B
- Total debt
- 20.71B
- Return on equity
- -11040.00%
- Short % of float
- 1.46%
About Bausch Health Companies Inc.
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, Czech Republic, Slovakia, Ukraine, Bulgaria, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- Website
- bauschhealth.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on BHC.TO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| APPIO THOMAS J | Chief Executive Officer | Stock Award(Grant) | Feb 24, 2026 | 3,620,030 |
| CARSON SEANA LYNNE | General Counsel | Sale | Mar 2, 2026 | 616,761 |
| CHARHON JEAN-JACQUES | Chief Financial Officer | Stock Award(Grant) | Feb 24, 2026 | 755,538 |
| KAVANAGH SARAH BALDWIN | Director | Stock Award(Grant) | May 21, 2026 | 282,230 |
| LENAR AIMEE J | Officer | Sale | Aug 18, 2026 | 334,853 |
| MILLER STEVEN D | Director | Stock Award(Grant) | May 15, 2025 | 239,224 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| PAULSON & CO. INC. | 19.57% | 73,255,869 | 917.16M | Sep 29, 2026 |
| Goldentree Asset Management LP | 9.26% | 34,665,731 | 434.01M | Sep 29, 2026 |
| Royal Bank of Canada | 2.45% | 9,187,080 | 115.02M | Sep 29, 2026 |
| Goldman Sachs Group Inc | 2.07% | 7,748,378 | 97.01M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 1.99% | 7,444,589 | 93.21M | Sep 29, 2026 |
| Two Sigma Investments, LP | 1.98% | 7,410,215 | 92.78M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund | 1.00% | 3,762,192 | 47.10M | Jul 30, 2026 |
| VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund | 0.66% | 2,481,313 | 31.07M | Jun 29, 2026 |
| SCHWAB STRATEGIC TRUST-Schwab Fundamental International Equity ETF | 0.43% | 1,617,412 | 20.25M | Aug 30, 2026 |
| VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Small-Cap | 0.26% | 986,066 | 12.35M | Jul 30, 2026 |
| DFA INVESTMENT TRUST CO-The Canadian Small Company Series | 0.22% | 815,010 | 10.20M | Jul 30, 2026 |
| DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT. | 0.16% | 594,511 | 7.44M | Jul 30, 2026 |
